Literature DB >> 789044

Drug-induced antinuclear antibodies and lupus syndromes.

D Alarcón-Segovia.   

Abstract

Drugs capable of triggering the onset of systemic lupus erythematosus may be divided into those that do so by pharmacological properties of their own and those that do so by eliciting allergic reactions which bring about lupus. Drugs in the first group vary in their potency to activate lupus. They all elicit antinuclear antibodies in the majority of patients who receive them but they only cause lupus in a small percentage of patients. This dichotomy suggests that a predisposition is required for the development of lupus upon intake of these drugs. The mechanism whereby these drugs elicit antinuclear antibodies seems to relate to coupling to and/or modification of, nuclear antigens. The patterns of antinuclear antibodies elicited by these drugs in individuals who receive them correlate well with their known reactivity with various nuclear antigens.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 789044     DOI: 10.2165/00003495-197612010-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  52 in total

1.  CLINICAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. COMPUTER ANALYSIS OF 520 CASES.

Authors:  E L DUBOIS; D L TUFFANELLI
Journal:  JAMA       Date:  1964-10-12       Impact factor: 56.272

2.  LUPUS DIATHESIS AND THE HYDRALAZINE SYNDROME.

Authors:  D ALARCON SEGOVIA; J W WORTHINGTON; L E WARD; K G WAKIM
Journal:  N Engl J Med       Date:  1965-03-04       Impact factor: 91.245

3.  INTERACTION OF THE RADICAL ION OF CHLORPROMAZINE WITH DEOXYRIBONUCLEIC ACID.

Authors:  S I OHNISHI; H M MCCONNELL
Journal:  J Am Chem Soc       Date:  1965-05-20       Impact factor: 15.419

4.  Rheumatic and febrile syndrome during prolonged hydralazine treatment.

Authors:  H P DUSTAN; R D TAYLOR; A C CORCORAN
Journal:  J Am Med Assoc       Date:  1954-01-02

5.  Severe reactions to long-acting sulfonamides. Erythema multiforme exudativum and lupus erythematosus following administration of sulfamethoxypyridazine and sulfadimethoxine.

Authors:  M L RALLISON; J O'BRIEN; R A GOOD
Journal:  Pediatrics       Date:  1961-12       Impact factor: 7.124

6.  Lupus-like syndrome induced by procainamide.

Authors:  A M Fakhro; R F Ritchie; B Lown
Journal:  Am J Cardiol       Date:  1967-09       Impact factor: 2.778

7.  Autoantibodies related to treatment with chlorthalidone and alpha-methyldopa.

Authors:  T E Feltkamp; E J Mees; M G Nieuwenhuis
Journal:  Acta Med Scand       Date:  1970-03-03

8.  Antibodies to nucleoprotein and to hydrazide-altered soluble nucleoprotein in tuberculous patients receiving isoniazid.

Authors:  D Alarcón-Segovia; E Fishbein; V M Betancourt
Journal:  Clin Exp Immunol       Date:  1969-10       Impact factor: 4.330

9.  Procainamide hydrochloride and lupus erythematosus.

Authors:  R Paine
Journal:  JAMA       Date:  1965-10-04       Impact factor: 56.272

10.  The acetylator phenotype of patients with systemic lupus erythematosus.

Authors:  M M Reidenberg; J H Martin
Journal:  Drug Metab Dispos       Date:  1974 Jan-Feb       Impact factor: 3.922

View more
  17 in total

Review 1.  Drug-induced lung disease.

Authors:  P Cole
Journal:  Drugs       Date:  1977-06       Impact factor: 9.546

2.  Prazosin treatment complicated by acute febrile polyarthritis.

Authors:  S A Cairns; S C Jordan
Journal:  Br Med J       Date:  1976-12-11

Review 3.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

4.  Chest diseases-epitomes of progress: pulmonary reactions to drug therapy.

Authors:  J A Burton
Journal:  West J Med       Date:  1977-10

Review 5.  Selecting appropriate antihypertensive drug dosages.

Authors:  G D Johnston
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 6.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

Review 7.  Disease and acetylation polymorphism.

Authors:  P K Lunde; K Frislid; V Hansteen
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

8.  The delayed appearance of an antinuclear factor and the diagnosis of systemic lupus erythematosus in glomerulonephritis.

Authors:  S A Cairns; E J Acheson; C L Corbett; S Dosa; N P Mallick; W Lawler; G Williams
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

9.  Increased presence of common systemic lupus erythematosus (SLE) anti-DNA idiotypes (16/6 Id, 32/15 Id) is induced by procainamide.

Authors:  Y Shoenfeld; Y Vilner; T Reshef; A Klajman; A Skibin; O Kooperman; R C Kennedy
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

10.  Acetylator phenotype in spontaneous SLE and rheumatoid arthritis.

Authors:  D H Lawson; D A Henry; J Lowe; P Reavey; J A Rennie; A Solomon
Journal:  Ann Rheum Dis       Date:  1979-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.